142 related articles for article (PubMed ID: 12670781)
21. Bronchodilator responsiveness in patients with COPD.
Tashkin DP; Celli B; Decramer M; Liu D; Burkhart D; Cassino C; Kesten S
Eur Respir J; 2008 Apr; 31(4):742-50. PubMed ID: 18256071
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease.
Paggiaro PL; Vagaggini B; Di Franco A; Zingoni M; Fano M; Biraghi M
Respiration; 2006; 73(5):603-9. PubMed ID: 16293958
[TBL] [Abstract][Full Text] [Related]
23. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast.
Zussman BD; Davie CC; Kelly J; Murdoch RD; Clark DJ; Schofield JP; Walls C; Birrell C; Webber D; Quinlan J; Ritchie SY; Carr A
Pharmacotherapy; 2001 Jun; 21(6):653-60. PubMed ID: 11401178
[TBL] [Abstract][Full Text] [Related]
24. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department.
Rodrigo GJ; Rodrigo C
Am J Respir Crit Care Med; 2000 Jun; 161(6):1862-8. PubMed ID: 10852758
[TBL] [Abstract][Full Text] [Related]
25. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of cilomilast in COPD.
Rennard S; Knobil K; Rabe KF; Morris A; Schachter N; Locantore N; Canonica WG; Zhu Y; Barnhart F
Drugs; 2008; 68 Suppl 2():3-57. PubMed ID: 19105585
[TBL] [Abstract][Full Text] [Related]
27. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD.
Wolkove N; Kamel H; Rotaple M; Baltzan MA
Chest; 2002 Mar; 121(3):702-7. PubMed ID: 11888949
[TBL] [Abstract][Full Text] [Related]
28. Concomitant use of ipratropium and tiotropium in chronic obstructive pulmonary disease.
Cole JM; Sheehan AH; Jordan JK
Ann Pharmacother; 2012 Dec; 46(12):1717-21. PubMed ID: 23170031
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease].
Zheng JP; Kang J; Cai BQ; Zhou X; Cao ZL; Bai CX; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):363-7. PubMed ID: 17045014
[TBL] [Abstract][Full Text] [Related]
30. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD.
Brophy C; Kastelik J; Gardiner E; Greenstone M
Chron Respir Dis; 2008; 5(1):13-8. PubMed ID: 18303097
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
[TBL] [Abstract][Full Text] [Related]
32. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
34. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
35. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
36. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Ouagued M; Martin-Chouly CA; Brinchault G; Leportier-Comoy C; Depincé A; Bertrand C; Lagente V; Belleguic C; Pruniaux MP
Pulm Pharmacol Ther; 2005; 18(1):49-54. PubMed ID: 15607127
[TBL] [Abstract][Full Text] [Related]
37. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
38. Reversibility of inspiratory lung function parameters after short-term bronchodilators in COPD.
Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
Respir Physiol Neurobiol; 2010 Aug; 173(1):58-63. PubMed ID: 20601207
[TBL] [Abstract][Full Text] [Related]
39. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.
Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
Respirology; 2006 Sep; 11(5):598-602. PubMed ID: 16916333
[TBL] [Abstract][Full Text] [Related]
40. Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?
Kerstjens HA; Timens W
Am J Respir Crit Care Med; 2003 Oct; 168(8):914-5. PubMed ID: 14555456
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
